Aura Biosciences, Inc. submitted its quarterly report on Form 10-Q covering the period ended September 30, 2026, disclosing operational risks, development status of its sole product candidate bel-sar, and a share count of 104,074,302 shares of common stock outstanding as of November 4, 2026.

Key Highlights

  • Shares outstanding: As of November 4, 2026, Aura Biosciences reported 104,074,302 shares of common stock, par value $0.00001 per share, outstanding.
  • Sole product candidate: According to the filing, the company is "heavily dependent on the success of belzupacap sarotalocan, or bel-sar," its only product candidate to date.
  • Phase 3 enrollment complete: The filing states the company has completed enrollment in its pivotal Phase 3 clinical trial for bel-sar, targeting early choroidal melanoma.
  • Topline data timeline: The company disclosed it does not expect topline data from the Phase 3 trial until the second half of 2027.
  • No revenue generated: The filing notes the company has not yet commercialized any pharmaceutical products and has incurred significant net losses since inception.
  • Company classification: Aura Biosciences is designated as a non-accelerated filer, smaller reporting company, and emerging growth company in this filing.

Aura Biosciences Reports Phase 3 Progress and Key Risks for Bel-Sar

Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biopharmaceutical company headquartered at 80 Guest Street, Boston, MA, filed its Form 10-Q for the quarterly period ended September 30, 2026. The company's common stock is listed on the Nasdaq Global Market. The filing provides an update on the status of bel-sar, the company's only product candidate, which is being evaluated for the treatment of early choroidal melanoma, a rare ocular oncology indication.

According to the filing, Aura Biosciences has completed enrollment in its global pivotal Phase 3 clinical trial of bel-sar, conducted under a Special Protocol Assessment agreed upon with the U.S. Food and Drug Administration. However, the company disclosed that this agreement "does not guarantee any particular outcome from regulatory review, including ultimate approval." Topline data from the trial is not expected until the second half of 2027. The company relies on third-party contract development and manufacturing organizations, or CDMOs, for clinical supply of bel-sar, a dependency the filing identifies as a potential risk to supply adequacy and cost.

The filing enumerates several material risks. Among them, the company stated it "has incurred significant net losses since our inception" and anticipates continued losses going forward. The company also flagged risks related to capital raising, potential stockholder dilution, dependence on third-party clinical trial operators, and competitive pressures around intellectual property. Additionally, the filing identifies artificial intelligence as a source of security risk to the company's confidential and proprietary information. Principal stockholders and management hold a significant percentage of stock, which the filing notes gives them meaningful influence over stockholder-approved matters.

What Was Disclosed

Aura Biosciences filed its Form 10-Q for the quarter ended September 30, 2026, reporting 104,074,302 shares outstanding as of November 4, 2026. The filing describes the company's reliance on bel-sar as its sole pipeline asset, completed Phase 3 enrollment, an expected data readout in the second half of 2027, and a range of business, regulatory, and operational risks. No revenue from product sales has been generated to date, and the company remains in the clinical development stage.